Silicon Valley Bank Results Presentation Deck
Continued momentum from SVB Leerink - record quarterly revenue
Expect 2021 SVB Leerink revenue to be between $420M-$450M
SVB Leerink expands our solutions for
life science/healthcare clients
DIDI
BIOPHARMA
D
Equity
Research
MEDACorp
svb >
Institutional
Equities
M&A
Advisory
SVBLEERINK
Alternative
Equities
TOOLS &
DIAGNOSTICS
lu
wwwww
Leveraged
Finance
Structured
Finance/
Royalties
Convertible
Securities
MEDICAL
DEVICES
Equity
Capital
Markets
NEW
HEALTHCARE
SERVICES
ā
Q1'21 activity
SVB Leerink continues to capitalize on strong public markets:
32 book-run transactions in Q1 ($6.5B in aggregate deal value)
Expanded team and leadership; new Leveraged Finance and
Structured Finance practices
SVB LEERINK REVENUE*
$ Millions
Commissions
Investment
Banking
SVB Leerink
expenses*
+
62.9
16.0
46.9
+
158.4
16.9
141.5
108.4
16.2
92.2
FY'21 outlook key drivers
Shifting conditions may create volatility for market sensitive revenues:
150.9 166.7
24.4
17.4
Q1'20
Q2'20 Q3'20 Q4'20 Q1'21
$62.0M $108.7M $77.6M $130.7M $136.4M
+ Strengthening collaboration
133.4 142.3
* Non-GAAP financial measure. See "Use of non-GAAP Financial Measures" in our Q1 2021 Earnings Release and our non
GAAP reconciliations at the end of this presentation.
Investment banking revenue
Strong, but lower expected revenue relative to 2020's record
New hires and expertise
Deepening Healthcare Investment Banking practice and
expanding into Leveraged Finance and Structured Finance
Between Silicon Valley Bank and SVB Leerink
Commissions revenue
Sales and trading may benefit from market volatility
Q1 2021 Financial Highlights
28View entire presentation